Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,183.46 +1.57 (+0.13%)

Official Closing Price Updated: 4:10 PM EDT, Sep 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Could This Be Novo Nordisk’s Next Billion-Dollar Weight-Loss Product? ↗

Today 17:20 EDT

The drugmaker badly needs more clinical wins.

Via The Motley Fool

Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? ↗

Today 6:25 EDT

The biotech player could eventually rival big pharma companies.

Via The Motley Fool

2 Healthcare Stocks with Impressive Fundamentals and 1 Facing Challenges

Today 0:35 EDT

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

Via StockStory

Eli Lilly (NYSE:LLY) Fits a Dividend Quality Screen Despite Its Low Yield ↗

September 18, 2026

Via Chartmill

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? ↗

September 24, 2026

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Via The Motley Fool

Eli Lilly (LLY) Stock Is Up, What You Need To Know

September 24, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration ...

Via StockStory

Explore the top gainers and losers within the S&P500 index in today's session. ↗

September 24, 2026

Via Chartmill

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration ↗

September 24, 2026

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

Via The Motley Fool

Topics ETFs

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy? ↗

September 24, 2026

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.

Via The Motley Fool

Topics ETFs

Stanley Druckenmiller, Ken Griffin, and Cathie Wood Have at Least 1 Thing in Common: They All Own This Stock ↗

September 24, 2026

This company is a leader in a high-growth field.

Via The Motley Fool

XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks ↗

September 23, 2026

XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.

Via The Motley Fool

Topics ETFs

Could Retatrutide Be Worth $10 Billion to Eli Lilly? ↗

September 23, 2026

The company continues to dominate the weight loss market.

Via The Motley Fool

Topics Law Enforcement

Viking's Obesity Edge May Be Staying Power, Not Weight Loss ↗

September 23, 2026

Viking Therapeutics shares jumped 36% after VK2735 maintenance data showed patients kept most weight loss on less frequent dosing, though Phase 3 results and commercial funding remain unresolved.

Via MarketBeat

Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? ↗

September 23, 2026

Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.

Via MarketBeat

Topics Intellectual Property Lawsuit

Why Viking Therapeutics Stock Skyrocketed on Tuesday ↗

September 23, 2026

The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.

Via The Motley Fool

Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH ↗

September 22, 2026

IBBQ offers concentrated biotech exposure with lower costs and stronger recent returns, while IYH provides broader sector diversification and higher dividend income.

Via The Motley Fool

Topics ETFs

Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems ↗

September 22, 2026

Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?

Via The Motley Fool

VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? ↗

September 22, 2026

VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

Via The Motley Fool

Topics ETFs

Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring ↗

September 22, 2026

Oura's IPO targets a $12.8B-$14.1B valuation, pricing shares at $40-$44 ahead of its Nasdaq debut, backed by Eli Lilly interest and strong subscription revenue growth.

Via MarketBeat

Topics Initial Public Offering

Should Dividend Investors Buy Pfizer Stock for Its High Yield or Invest in Eli Lilly for Its Dividend Growth? ↗

September 22, 2026

When investing in a dividend stock, it's important to consider not just the yield, but also the potential for dividend growth and overall risk.

Via The Motley Fool

Topics Economy

Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall. ↗

September 22, 2026

Viking and Roche both reported positive results for their weight-loss drugs Tuesday.

Via Investor's Business Daily

2 Cash-Producing Stocks with Exciting Potential and 1 We Brush Off

September 22, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure Problem

September 21, 2026

Via AB Newswire

Topics Animal Testing

Eli Lilly Stock Is On Track to Do Something It Hasn't Done Since 2016 ↗

September 21, 2026

The top healthcare stock has been underperforming the market, and its returns haven't been as impressive as in recent years.

Via The Motley Fool

Meet the Vanguard ETF That Increased Its SpaceX Holding by 39% in 1 Month and Shows No Signs of Slowing Down ↗

September 20, 2026

The unlocking of SpaceX shares is reshaping the communications sector.

Via The Motley Fool

Topics ETFs

Why Twist Bioscience Stock Skyrocketed This Week ↗

September 18, 2026

It's plugging into a state-of-the-art research tool developed by a major pharmaceutical company.

Via The Motley Fool

Topics Artificial Intelligence

Better Buy for Cautious Investors: Eli Lilly vs Costco ↗

September 18, 2026

These companies may perform well in any market environment.

Via The Motley Fool

Topics Artificial Intelligence Economy

Automated Labeling Tools Are Modernizing the AI Training Dataset Market ↗

September 18, 2026

The global AI training dataset market was valued at USD 3.2 billion in 2025 and is projected to reach USD 16.3 billion by 2033, expanding from USD 3.9 bill

Via Talk Markets

Topics Artificial Intelligence

1 Safe-and-Steady Stock Worth Your Attention and 2 We Question

September 18, 2026

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Ch...

Via StockStory

Topics Emissions

Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. ↗

September 17, 2026

The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.